278798-07-5

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(1H-pyrazol-3-yl)-, 1,1-dimethylethyl ester
• Synonyms: 1-Piperidinecarboxylic acid, 4-(1H-pyrazol-3-yl)-, 1,1-dimethylethyl ester;tert-butyl 4-(1H-pyrazol-3-yl)piperidine-1-carboxylate
• CAS NO: 278798-07-5
• Molecular Formula: C₁₃H₂₁N₃O₂
• Molecular Weight: 251.32474
• Mol File: 278798-07-5.mol

Chemical Properties

• Boiling Point: 405.7±38.0 °C(Predicted)
• Appearance: /
• Density: 1.140±0.06 g/cm3(Predicted)
• PKA: 14.12±0.10(Predicted)
• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(1H-pyrazol-3-yl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(1H-pyrazol-3-yl)-, 1,1-dimethylethyl ester(278798-07-5)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(1H-pyrazol-3-yl)-, 1,1-dimethylethyl ester(278798-07-5)

Safety Data

• Hazardous Substances Data: 278798-07-5(Hazardous Substances Data)

Usage

Physical form

White solid

Melting point

88-90°C

Uses

Pharmaceutical research and development (as a building block for the synthesis of various bioactive compounds), production of agrochemicals, fragrances, and flavors

Biological activities

Potential to exhibit various biological activities due to its structural features, making it a valuable tool in drug discovery and development.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 1126-09-6 4-carbethoxypiperidine 
• 1799799-87-3 tert-butyl 4-[(E)-3-(dimethylamino)prop-2-enoyl]piperidine-1-carboxylate 
• 206989-61-9 4-acetyl-1-(t-butoxycarbonyl)piperidine 
• 690262-00-1 4-(1H-pyrazol-3-yl)piperidine dihydrochloride 

Downstream Products

• 787640-26-0 4-(1H-pyrazol-3-yl)piperidine hydrochloride salt 

Relevant articles and documents

TRPML MODULATORS

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase

Monoacylglycerol lipase (MAGL) is the main enzyme responsible for degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the CNS. MAGL catalyzes the conversion of 2-AG to arachidonic acid (AA), a precursor to the proinflammatory eicosannoids such as prostaglandins. Herein we describe highly efficient MAGL inhibitors, identified through a parallel medicinal chemistry approach that highlighted the improved efficiency of azetidine and piperidine-derived carbamates. The discovery and optimization of 3-substituted azetidine carbamate irreversible inhibitors of MAGL were aided by the generation of inhibitor-bound MAGL crystal structures. Compound 6, a highly efficient and selective MAGL inhibitor against recombinant enzyme and in a cellular context, was tested in vivo and shown to elevate central 2-AG levels at a 10 mg/kg dose.

1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS

The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

HETEROARYLPIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I): (wherein R>12345610 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.